Page 2 - Iontech News Today

Biopharma Stock Breaking News - BioNTech (Nasdaq: BNTX) and DualityBio Receive FDA Fast Track Designation

NEW YORK, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that...

Constructech Recognizes Projectmates Software as a 2024 Trusted Product...

BioNTech and its partner Duality Biologics said on Monday they initiated a late-stage trial testing their precision drug against a certain type of breast cancer, taking on a rival partnership between AstraZeneca and Daiichi Sankyo. COVID-19 vaccine maker BioNTech, which is renewing its focus on its traditional roots in oncology, said in a joint statement with China's Duality that their drug would be tested on women with a certain type of advanced breast cancer with low levels of a cell sur...

Market forces rained on the parade of BioNTech SE ( NASDAQ:BNTX ) shareholders today, when the analysts downgraded...

BioNTech SE (BNTX) said it projects total company revenues of approximately 3 billion euros for financial year 2024, mainly driven by the COVID-19 vaccine franchise which is expected to remain profitable given the cost sharing structure with its partner Pfizer Inc.

BioNTech, a leading biotechnology company, on Monday inaugurated its first manufacturing plant for mRNA vaccines in Africa in Rwanda capital of Kigali.....

BioNTech will develop and commission a state-of-the-art mRNA clinical-scale manufacturing facility at La Trobe University's Melbourne campus.

The Defense Departments COVID-19 vaccine mandate has been rescinded, but two ex-service members are still asking the Supreme Court to consider its constitutionality – in a case with the potentiality

COVID-19 vaccine maker BioNTech said on Tuesday the European Patent Office has declared as invalid an mRNA patent that has been invoked by Moderna in litigation about alleged an patent violation by BioNTech and its partner Pfizer. "We understand and welcome the European Patent Office’s decision to revoke Moderna’s European Patent 3 718 565 B1," the German biotech firm said in a statement. "The European Patent Office’s decision is an important one as we belie...